Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, will announce its Interim Results for the six months ended 30th June 2021 following a Board of Director’s meeting to be held on Tuesday 28th September 2021.
Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 12:00 ET / 17:00 BST / 18:00 CEST on September 29, 2021.
For more details or to attend the virtual briefing, please contact philogen@consilium-comms.com.
About Philogen
Philogen is a Swiss-Italian, fully integrated, biotech company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and small organic ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical candidates in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is listed on the Italian stock exchange and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com and www.philochem.com.
For more information please contact:
Philogen
Dr. Christian Lizak (Business Development) / Dr. Emanuele Puca (Investor Relations)
+41 (0) 43 544 88 00
christian.lizak@philogen.com / emanuele.puca@philogen.com
Consilium Strategic Communications
Mary-Jane Elliott, Davide Salvi
Philogen@consilium-comms.com
Source: Philogen S.p.A